Behaviorally’s Post

The latest issue of CHC Insight Europe features a review of STADA Group's recent Health report; other contents include coverage of the analgesics market across the region, plus the latest innovation and developments impacting CHC in Europe. For a sample issue, contact Melissa #CHC #CHCInsight #Insight #CHCInsightEurope #Europe #StadaHealthreport #analgesics

We welcome the recommendations put forth during the AMR Industry Alliance Call-to-Action in New York, particularly the emphasis on enhancing the responsible use of antimicrobials by prioritizing diagnostics through improved valuation and investment in diagnostics. Dive into the comprehensive report of these impactful recommendations: https://lnkd.in/d7BnW73A #AMR #AntimicrobialResistance #HealthcareInnovation

The latest issue of CHC Insight Europe is now available, featuring a full report from our recent European CHC Conference, detailing key learnings. This issue also includes coverage of the GI market across the region, plus the latest innovation, trends and developments impacting CHC in Europe. For a sample copy of this issue, contact Melissa #CHC #Insight #Europe #NHEU24 #GI #gastrointestinals

Join us for a live webinar tomorrow on World Environment Day (5th June) exploring AMR and the environment: The challenge of manufacturing and procuring antibiotics responsibly. AMR threatens to undermine the basis of modern medicine, but also has implications beyond human health, including domestic and wild animals, plants and the wider environment (including ecosystems). Accordingly, a “One Health” approach is necessary to prevent and control AMR. With insights and perspectives from a wide range of experts, this webinar will focus on the connection between human health and environmental pillars of One Health, and its link to the manufacturing of antibiotics. Featuring: Courtney Soulsby - Global Director. Healthcare & Life Sciences, BSI Gareth Morgan - Global Portfolio Management Head, Shionogi Inc. (U.S.) Elisabete Dias Ramos - Access Project Consultant, Global Antibiotic R&D Partnership (GARDP) Maneesh Paul. S., M. Sc., Ph.D., FIDSA., - Scientific Advisor, Orchid Pharma Sam Gunasekar - Senior Manager, Orchid Pharma Find out more and register here: https://lnkd.in/eHK5YcNc #Antimicrobialresistance #AMR #PublicHealth #SustainableHealthcare

💥 Pharma Brand Epi vs. Demand Based Forecast 💥 Ever wondered what difference between Epi- based and Demand- based forecast in pharma setting? 🤔   Well, Epidemiological-based forecast starts from country population, disease prevalence, diagnosis and treatment rate to work out the volume while Demand-based forecast starts from the current market volume, new category penetration rate, and brand preference to work out the brand volume. I pulled together the forecast funnel ( parameters’ library)  for both kind of forecast. I divided them to: •Patient funnel •Volume funnel •Revenue funnel  If you'd like a copy, please let me know in the comments ✍️👇 #pharmaforecast #brandforecast ……………………………………………….. Hi, I’m Fouad Akkad, I support pharma and Biotech companies to maximize the patients’ impact. - Please repost 🔁 if you think this resource may be of interest to your connections. - Please comment ✍️ if you’d like a copy in your inbox - For future posts/ resources, please follow and ring the bill 🔔 on my profile

The latest issue of CHC Insight Europe is now available, featuring a full report from our recent European CHC Conference, detailing key learnings. This issue also includes coverage of the GI market across the region, plus the latest innovation, trends and developments impacting CHC in Europe. For a sample copy of this issue, contact Melissa #CHC #Insight #Europe #NHEU24 #GI #gastrointestinals

Hot topic – diversity in early clinical trials – don’t miss the discussion at AGAH Annual Conference in April 2024 in Münster For many decades, early clinical trials adhered to established patterns, the common participant profile consisted of a young, healthy, Caucasian male with regular BMI and non-vegetarian dietary habits. This limited diversity raised concerns about the generalizability of research findings to broader populations. With a growing awareness, researchers frequently take various factors into consideration.   Following an overview of guidelines concerning the trial population in early-phase clinical trials by Dr. Kerstin Breithaupt-Grögler, MD Breithaupt-Grögler from -kbr-clinical pharmacology services, we will engage in a structered discussion with the audience. Brief introductions on ethnicity by Klaus Francke from Bayer, women of child-bearing potential and BMI by Christine Klipping from Dinox, nutritional habits by Sybille Baumann from CRS Berlin and age by Kerstin Breithaupt and Sybille Baumann will set the stage for the main topics. Klaus Francke will elaborate on how a sponsor adapts to the increasing need for diversity in early-phase clinical trials.   #ClinicalTrials #WomenInClinicalTrials #NutritionHabits #ParticipantProfile

The last two days we hosted Chi Pakarinen from MediPaCe to work together on patient centric sampling and its application in #lifesciences and #biomarkers. Helen Gika, Chi Pakarinen, Martha Chalkopoulou, Olga Begou We thank Chi for the visit and the open collaboration. #publichealth, #clinicalresearch, #driedbloodspot,

Explore the growing uses for registry data in drug development. Join our webinar this week to learn more. #registry #realworld data #rwd

🌟 Super early bird discount alert! 🌟 Don't miss out on the opportunity to join us at the 7th Annual MarketsandMarkets Real-World Evidence and Life Sciences Analytics Conference, happening on October 17th - 18th, 2024 in Boston! Our conference is set to bring together a diverse range of experts, leaders, and stakeholders, all converging to share insights and perspectives on crucial industry points. With a focus on best practices, attendees will engage in discussions aimed at enhancing decision-making processes. Real-World Evidence (RWE) solutions stand at the forefront of innovation, offering invaluable tools for both industrial and academic researchers. Through digitally connected platforms, RWE enables continuous patient monitoring and facilitates the organization and evaluation of clinical data for regulatory submissions. However, as the field of RWE research continues to evolve, it becomes increasingly evident that certain gaps remain unexplored. That's why our conference aims to provide guidance and foster consensus on essential annotations, ultimately driving the effective utilization of real-world data. Take advantage of this chance to stay ahead in this dynamic field by grabbing your super early bird discount now! Come to Boston for two days of unmatched learning, networking, and collaboration. Don't wait - register today and enjoy savings! DM or reach out to me at nikhil.jain@marketsandmarkets.com to know more! Note: Discounts are valid only until 25th May for first 30 registrants. To learn more about the conference: https://lnkd.in/d4kqnDf4 #RWE #LifeSciences #Analytics #Boston #EarlyBirdSpecial #realworlddata #realworldevidence #healthcare #advancedmedicine #lifesciencesanalytics #lifesciences #conference2024 #healthcare #pharma #marketsandmarkets #RWDL2024 #bostonconference2024 #rwdlboston2024